Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Disclosing the true impact of screening endoscopy on colorectal cancer incidence

Thomas Heisser, Carlo Senore, Michael Hoffmeister, Lina Jansen, Hermann Brenner
doi: https://doi.org/10.1101/2022.11.22.22282622
Thomas Heisser
1Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
2Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany
Roles: (Doctoral Researcher)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: t.heisser{at}dkfz.de
Carlo Senore
3Epidemiology and Screening Unit – CPO, University Hospital Città della Salute e della Scienza, Turin, Italy
Roles: (Senior Epidemiologist)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Hoffmeister
1Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
Roles: (Associate Professor of Epidemiology)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lina Jansen
4Epidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center (DKFZ), Heidelberg, Germany
Roles: (Senior Epidemiologist)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hermann Brenner
1Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
5Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
6German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
Roles: (Professor of Epidemiology)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives Randomized trials have demonstrated reduction of colorectal cancer (CRC) incidence by screening endoscopy. However, measured reduction underestimates true reduction due to inclusion of preclinical cases already present at recruitment. We aimed to quantify the true impact of screening endoscopy on reducing the CRC incidence.

Design Simulation study replicating reported CRC incidence by SCORE, a large, randomized screening sigmoidoscopy trial, and deriving expected incidence after excluding cases that manifested during follow-up but were already prevalent at baseline.

Setting Offer of a single flexible sigmoidoscopy in an organised, population-based screening setting.

Participants Simulated, sex- and age-matched SCORE trial population (intervention group, N=17,136, control group, N=17,136, 50% women, ages 55-64 at baseline).

Interventions Screening flexible sigmoidoscopy versus no screening.

Main outcome measure ‘True’ (i.e., unbiased, excluding prevalent cancers at baseline) and ‘apparent’ (i.e., as reported) incidence rate ratios (IRR) for screening versus no screening.

Results In the initial years after randomization, apparent cumulative incidence in the screening group was higher than in the control group due to inclusion of a large proportion of prevalent cancers. In the longer run, apparent cumulative incidence was lower in the screening group, but this incidence reduction was still much lower than true incidence reduction due to inclusion of prevalent cases in calculation of apparent cumulative incidence. In intention-to-screen analysis, apparent/true risk reductions after 8, 11 and 15 years of follow-up were 16%/31%, 20%/28%, and 21/25%, respectively. In per-protocol analyses, respective apparent/true risk reductions were 28%/54%, 34%/49%, and 35%/44%. Estimated underestimation of true incidence was similar among men and women and among age groups 55-59 and 60-64.

Conclusions The preventive effect of screening endoscopy is likely much stronger than reflected in the reported apparent IRRs. Published findings of randomized screening trials underestimate the true preventive effective of screening endoscopy even after 15 year or longer follow-up.

What is already known on this topic

  • - Several large-scale randomized trials have demonstrated substantial reduction of colorectal cancer incidence by endoscopic screening.

  • - In these trials, the preventive effect of screening endoscopy only transpires after 4-6 years, as screen-detected, prevalent cancers (which can no longer be prevented) dominate the measured incidence in the first years of follow-up.

  • - The true impact of screening endoscopy on CRC incidence is therefore essentially unknown.

What this study adds

  • This modelling study derives estimates of the apparent and true impact of screening sigmoidoscopy on reducing the CRC incidence by accounting for prevalent preclinical cancers at baseline.

  • After careful calibration, the model closely predicts observed effects on CRC incidence in the SCORE trial, a randomized trial of flexible sigmoidoscopy conducted in Italy, and demonstrates that the endoscopy screening effect on incidence might be substantially larger when accounting for prevalent preclinical cancers at baseline.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Financial support for this study was provided in part by a grant by the German Federal Ministry of Education and Research (grant number 01GL1712). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Declarations

  • Funding: Financial support for this study was provided in part by a grant by the German Federal Ministry of Education and Research (grant number 01GL1712). The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report.

  • Conflict of interest: The authors declare no conflicts of interest.

  • Ethics approval: Not required.

  • Consent to participate and for publication: Not required.

  • Availability of data, code and material: All analyses relevant to the study are included in the article or uploaded as supplementary information. The model source code is available from https://www.dkfz.de/en/klinepi/download/index.html. Further information is available from the corresponding author upon request.

  • Authors’ contributions: HB and TH designed the study and developed the methodology. TH conducted the statistical analyses and drafted the manuscript. All authors critically reviewed the manuscript, contributed to its revision, and approved the final version submitted. The researchers are independent from funders. All authors had full access to all of the data used for the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Data Availability

All analyses relevant to the study are included in the article or uploaded as supplementary information. The model source code is available from https://www.dkfz.de/en/klinepi/download/index.html. Further information is available from the corresponding author upon request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 27, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Disclosing the true impact of screening endoscopy on colorectal cancer incidence
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Disclosing the true impact of screening endoscopy on colorectal cancer incidence
Thomas Heisser, Carlo Senore, Michael Hoffmeister, Lina Jansen, Hermann Brenner
medRxiv 2022.11.22.22282622; doi: https://doi.org/10.1101/2022.11.22.22282622
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Disclosing the true impact of screening endoscopy on colorectal cancer incidence
Thomas Heisser, Carlo Senore, Michael Hoffmeister, Lina Jansen, Hermann Brenner
medRxiv 2022.11.22.22282622; doi: https://doi.org/10.1101/2022.11.22.22282622

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)